An investigational monoclonal antibody aimed at non-Hodgkin lymphoma fared well in a test against rituximab (Rituxan), a researcher reported here.
< READ MORE >

MEMPHIS, Tenn., Jan. 14 -- A newly identified subtype of pediatric T-cell acute lymphoblastic leukemia may predict poor response to standard lymphoid-cell-directed chemotherapy.  <READ MORE>

HEIDELBERG, Germany, Sept. 10 -- Survival rates for the four major childhood blood cancers are continuing to rise, researchers here said.     <READ MORE>

Aug 6, 2008
CLL Phenotype Confers Malignancy Risk in Lymphocytosis

LEEDS, England, Aug. 6 -- More than 5% of people with normal blood counts have chronic lymphocytic leukemia-phenotype B cells, as do almost 15% of those with monoclonal B-cell lymphocytosis, investigators here have found.  <READ MORE>

Apr 30, 2008
Genotyping Predicts Risk and Outcome in AML

ULM, Germany, April 30 -- Genotyping of acute myeloid leukemia can risk-stratify and predict response to treatment in patients with cytogenetically normal leukemic cells, investigators in a European cooperative study group have found.  <READ MORE>

Mar 7, 2008
Pregnant CML Patients Face Congenital Dilemma with Imatinib (Gleevec)

LONDON, March 7 -- Pregnancy during therapy for chronic myelogenous leukemia puts women in a life-threatening predicament: a choice between the possible teratogenic effects of imatinib (Gleevec) and the need to keep the disease quiescent.  <READ MORE>

Dec 12, 2007
ASH: Newer Agents Vie for CML Niche in Imatinib Failure

ATLANTA, Dec. 12 -- Chronic myelogenous leukemia patients who are resistant or intolerant to imatinib (Gleevec) had a high response rate when treated with dasatinib (Sprycel), researchers reported here.  <READ MORE>

Dec 12, 2007
ASH: Intensified Kids' Regimen for ALL in Adults Shows Promise

ATLANTA, Dec. 12 -- Adults with acute lymphoblastic leukemia have had almost a doubling of survival compared with historical rates when treated with an intensified pediatric regimen, investigators said here.  <READ MORE>

Dec 10, 2007
ASH: Adding Antisense Agent to Chemotherapy Improves Survival in Relapsed CLL

ATLANTA, Dec. 11 -- Oblimersen (Genasense) added to chemotherapy produced a significant improvement in long-term survival in patients with relapsed or refractory chronic lymphocytic leukemia compared with chemotherapy alone, researchers said here.  <READ MORE>

Oct 5, 2007
Thalidomide Improves Survival for Older Multiple Myeloma Patients

LILLE, France, Oct. 5 -- Older treatment-naïve stages II or III multiple myeloma patients have a survival advantage when thalidomide (Thalomid) is added to standard therapy, researchers found in a randomized trial.  <READ MORE>

August 30, 2007
Missing Gene May Spark Imatinib Resistance in Philadelphia Chromosome-positive ALL

MEMPHIS, Tenn., Aug. 30 -- When imatinib (Gleevec) therapy fails in Philadelphia chromosome-positive acute lymphocytic leukemia (ALL), it may be because the B-cells involved lack a critical tumor-suppressor gene, researchers here said.  <READ MORE>